Cogent Biosciences, Inc.
COGT
Peringkat dalam Saham
#3264
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Harga Saham
$31.47
Kapitalisasi Pasar
$5.46B
Perubahan (1 hari)
4.85%
Perubahan (1 tahun)
93.99%
Negara
US
Perdagangan Cogent Biosciences, Inc. (COGT)
Kategori
Healthcare
Laba untuk Cogent Biosciences, Inc. (COGT)
Laba pada Jun 2026 TTM: $-377.18M
Menurut laporan keuangan terbaru dari Cogent Biosciences, Inc., laba saat ini perusahaan adalah $-377.18M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-192.41M, penurunan dibandingkan dengan laba tahun 2022 sebesar $-140.24M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Cogent Biosciences, Inc. dari 2015 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $-377.18M | 47.42% |
| 2024 | $-255.86M | 32.98% |
| 2023 | $-192.41M | 37.20% |
| 2022 | $-140.24M | 94.04% |
| 2021 | $-72.27M | -3.39% |
| 2020 | $-74.81M | 135.00% |
| 2019 | $-31.83M | -7.82% |
| 2018 | $-34.53M | 35.46% |
| 2017 | $-25.49M | 40.65% |
| 2016 | $-18.12M | 174.94% |
| 2015 | $-6.59M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | -1,498.51% |
US
|
|
| $-3.09B | 718.44% |
US
|
|
| $-4.02B | 964.80% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -617.17% |
NL
|
